Clinical trial NCT04961164: Resistant Starch Prebiotic Effects in Chronic Kidney Disease
Official title: A Randomized Double-Blind Cross-over Trial to Study the Effects of Resistant Starch Prebiotic Effects in Chronic Kidney Disease (ReSPECKD)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Kidney Diseases
Keywords: Chronic Kidney Disease
Resistant Potato Starch
uremic toxins (indoxyl sulphate, p-cresyl sulphate)
gut microbiota
metabolomics
Lead sponsor: University of Manitoba
Sponsor class: OTHER
First posted: 2021-07-14
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: In patients with Chronic Kidney Disease (CKD), there is a buildup of nitrogenous uremic toxins of gut microbiome origin, which can contribute to uremic symptoms, reduced quality of life, and earlier progression to dialysis. The goal of this project is to investigate whether the consumption of resistant potato starch (RPS) as an adjunctive therapy to current standard of CKD care will reduce uremic toxins and symptoms by altering the gut microbiota in patients with CKD.

Detailed description: Participants will consent to follow a 18-week study regimen. Participants will receive 2 sachets per day containing either 15 grams of RPS or 15 grams corn starch. The powder in the sachets will be mixed in water and consumed, one sachet in the morning and one before bed. Participants will be instructed to consume the investigational product at least 2 hours prior to or after taking any medication.

For the first two weeks, all participants will go through a run-in period, where they will receive the corn starch. During weeks 3 to 8 (period 1) participants will receive either RPS or cornstarch. The first treatment received will be determined by randomization procedures. During weeks 9 to 12, all participants will undergo a washout period where they will consume cornstarch. During weeks 13 and 18 (period 2), participants will receive the treatment they did not previously consume.

Eligibility criteria: Inclusion Criteria:

* Participant is willing and able to give informed consent for participation in the trial.
* Participant has the ability to speak and read English.
* Male or Female, aged 18 years or above. Females of child-bearing potential must agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include: Hormonal contraceptives including oral contraceptives, hormone birth control patch, vaginal contraceptive ring, injectable contraceptives, or hormone implant, double-barrier method, intrauterine devices, non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s), vasectomy of partner at least 6 months prior to screening.
* Estimated glomerular filtration rate (eGFR) \<15 mL/min/1.73m\^2 for the past 3 months
* In the Investigator's opinion, participant is able and willing to comply with all trial requirements.

Exclusion Criteria:

* The participant is cognitively impaired and cannot give consent or participate in the group program
* The participant has an existing relationship with the research team, such as supervisory relationship (student, employee) or familial relationship (child, spouse, etc)
* Participants who indicate that they cannot consume study treatments.
* Participants who indicates they are allergic to potatoes or corn
* Female participant who is pregnant, lactating or planning pregnancy during the course of the trial.
* History of renal transplant, ongoing dialysis, use of antibiotics (last 3-months), bowel diseases, cancer, surgically removed bowel, or any gastrointestinal surgery (e.g. intestinal resection, gastric bypass, colorectal surgery)
* Inability to consume treatment due to swallowing or GI issues and inability to obtain written informed consent.
* Participating in another interventional trial that could influence the intervention or outcome of this trial.
* Participants with uncontrolled diabetes with a hemoglobin A1C \> 10%.
* Participants who consume probiotic supplements.
* Participants with abnormal constrictions of the gastrointestinal tract, diseases of the oesophagus and/or the superior opening of the stomach (cardia), potential or existing intestinal blockage, paralysis of the intestine, megacolon, faecal impaction, appendicitis, a sudden change in bowel habits that has persisted for more than 2 weeks, undiagnosed rectal bleeding, or failure to defaecate following the use of another laxative prod.
* Participants with severe anemia (hemoglobin less than 70).
* Participants taking medications which inhibit peristaltic movement (e.g. opioids,loperamide).
* Participants taking other fiber supplements or able to maintain high fiber/adequate fiber intake through diet.

Primary outcomes:
measure: Change in blood uremic toxin, indoxyl sulphate, between treatments
timeFrame: between endpoints of each experimental period (week 8 to week 18)
measure: Change in blood uremic toxin, p-cresyl sulphate, between treatments
timeFrame: between endpoints of each experimental period (week 8 to week 18)
Secondary outcomes:
measure: Change in symptoms score using the Edmonton Symptom Assessment Scale between treatments
timeFrame: between endpoints of each experimental period (week 8 to week 18)
measure: Change in quality of life of participants between treatments
timeFrame: between endpoints of each experimental period (week 8 to week 18)
measure: Change in alpha diversity of the gut microbiome between treatments
timeFrame: between endpoints of each experimental period (week 8 to week 18)
measure: Change in beta diversity of the gut microbiome between treatments
timeFrame: between endpoints of each experimental period (week 8 to week 18)
measure: Change in differential abundance in the gut microbiome between treatments
timeFrame: between endpoints of each experimental period (week 8 to week 18)
Other outcomes:
measure: Change in waist circumference
timeFrame: between endpoints of each experimental period (week 8 to week 18)
measure: Change in body weight
timeFrame: between endpoints of each experimental period (week 8 to week 18)
measure: Change in serum glucose
timeFrame: between endpoints of each experimental period (week 8 to week 18)
measure: Change in Hemoglobin A1c
timeFrame: between endpoints of each experimental period (week 8 to week 18)
measure: Change in urinary total protein
timeFrame: between endpoints of each experimental period (week 8 to week 18)
measure: Change in urinary glucose concentration
timeFrame: between endpoints of each experimental period (week 8 to week 18)
measure: Change in urinary albumin/creatinine ratio
timeFrame: between endpoints of each experimental period (week 8 to week 18)
Locations:
city: Winnipeg
country: Canada
facility: Chronic Disease Innovation Centre, Seven Oaks Hospital
state: Manitoba
city: Winnipeg
country: Canada
facility: Health Science Centre (HSC)
state: Manitoba
Study officials:
affiliation: University of Manitoba
name: Dylan Mackay, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Shamloo M, Mollard R, Wang H, Kingra K, Tangri N, MacKay D. A randomized double-blind cross-over trial to study the effects of resistant starch prebiotic in chronic kidney disease (ReSPECKD). Trials. 2022 Jan 24;23(1):72. doi: 10.1186/s13063-022-06009-1.